{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:26:24Z","timestamp":1775219184112,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejca.2023.04.018","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T12:12:43Z","timestamp":1682683963000},"page":"98-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids"],"prefix":"10.1016","volume":"188","author":[{"given":"Simona","family":"Manacorda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria De Toro","family":"Carmena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-2061","authenticated-orcid":false,"given":"Ciara","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Mo","family":"Linh Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.S.","family":"Furness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.04.018_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2023.04.018_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJMsb2019760","article-title":"The rapid rise in cutaneous melanoma diagnoses","volume":"384","author":"Welch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.018_bib3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pcmr.12538","article-title":"Melanoma central nervous system metastases: current approaches, challenges, and opportunities","volume":"29","author":"Cohen","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2023.04.018_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.04.018_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0002-9610(78)90171-X","article-title":"Metastatic pattern of malignant melanoma. A study of 216 autopsy cases","volume":"135","author":"Patel","year":"1978","journal-title":"Am J Surg"},{"key":"10.1016\/j.ejca.2023.04.018_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ejca.2023.04.018_bib7","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/ijc.33162","article-title":"Real-world outcomes of advanced melanoma patients not represented in phase III trials","volume":"147","author":"van Zeijl","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2023.04.018_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2023.04.018_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with Nivolumab Plus Ipilimumab or Nivolumab alone versus Ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.018_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.018_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.04.018_bib12","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Approved by the ESMO Guidelines Committee: February 2002, last update September 2019","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.04.018_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.018_bib14","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2023.04.018_bib15","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","article-title":"Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets)","volume":"39","author":"Long","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.018_bib16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMe1807752","article-title":"Immunotherapy for melanoma metastatic to the brain","volume":"379","author":"Turajlic","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.018_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102083","article-title":"Melanoma brain metastases - interdisciplinary management recommendations 2020","volume":"89","author":"Gutzmer","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2023.04.018_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2023.04.018_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.04.018_bib20","unstructured":"R Core Team. R: a language and environment for statistical computing; 2020."},{"key":"10.1016\/j.ejca.2023.04.018_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.04.018_bib22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1470-2045(22)00452-1","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","volume":"23","author":"Dummer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.04.018_bib23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.04.018_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00566-6","article-title":"Symptomatic melanoma CNS metastases in the TRICOTEL study","volume":"23","author":"Schmitt","year":"2022","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2023.04.018_bib25","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ejca.2023.04.018_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2023.04.018_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","article-title":"The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline","volume":"96","author":"Ryken","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2023.04.018_bib28","doi-asserted-by":"crossref","first-page":"v555","DOI":"10.1093\/annonc\/mdz255.049","article-title":"Outcomes of patients with melanoma brain metastases (MBM) treated with standard of care therapy after being excluded from MBM-specific clinical trials","volume":"30","author":"Holbrook","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.04.018_bib29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/acem.14513","article-title":"Pragmatic clinical trial design in emergency medicine: Study considerations and design types","volume":"29","author":"Gettel","year":"2022","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.ejca.2023.04.018_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1747016117733506","article-title":"Pragmatic clinical trials and the consent process","volume":"14","author":"Murdoch","year":"2018","journal-title":"Res Ethics"},{"issue":"11","key":"10.1016\/j.ejca.2023.04.018_bib31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Keilholz","year":"2020","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:29Z","timestamp":1760733629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923002216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":31,"alternative-id":["S0959804923002216"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}